Vivoryon Therapeutics N.V.
ISIN: NL00150002Q7
WKN: A2QJV6
07 March 2022 07:00AM

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference

Vivoryon Therapeutics N.V. · ISIN: NL00150002Q7 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1295071

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference

07.03.2022 / 07:00
The issuer is solely responsible for the content of this announcement.


 

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
 

HALLE (SAALE) / MUNICH, GERMANY, March 7, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, will present at the following conference:


BioCapital Europe 2022
Date: March 10, 2022, 10:00 am CET
Venue: Amsterdam, The Netherlands
Presenter: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics N.V.

A webcast of the presentation will be available from March 11, 2022 via the "Presentations & Webcasts" page in the Investor Relations section on the Company's website at www.vivoryon.com and will be archived on the Company's website for 30 days following the conference.
 

###


About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com


Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the "Company"), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: IR@vivoryon.com


Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu
 



07.03.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vivoryon Therapeutics N.V.
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: contact@vivoryon.com
Internet: www.vivoryon.com
ISIN: NL00150002Q7
WKN: A2QJV6
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1295071

 
End of News DGAP News Service

1295071  07.03.2022 

fncls.ssp?fn=show_t_gif&application_id=1295071&application_name=news&site_id=boersengefluester_html

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 0,00 0,00 0,00 10,76 0,00 0,00 0,00
EBITDA1,2 -7,68 -7,63 -15,87 -12,63 -28,95 -28,67 0,00
EBITDA-Margin3 0,00 0,00 0,00 -117,38 0,00 0,00 0,00
EBIT1,4 -7,70 -7,72 -16,01 -12,79 -29,11 -28,84 0,00
EBIT-Margin5 0,00 0,00 0,00 -118,87 0,00 0,00 0,00
Net Profit (Loss)1 -7,74 -7,82 -16,51 -12,66 -28,16 -28,34 0,00
Net-Margin6 0,00 0,00 0,00 -117,66 0,00 0,00 0,00
Cashflow1,7 -6,99 -11,61 -14,01 -11,26 -21,79 -21,54 0,00
Earnings per share8 -0,94 -0,62 -0,83 -0,63 -1,28 -1,12 -0,87
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Vivoryon Therapeutics
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A2QJV6 NL00150002Q7 N.V. 49,74 Mio € 27.10.2014 Verkaufen 9F3HFWXR+56
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
-4,77 0,00 0,00 -1,73 1,89 -2,31 0,00
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
21.06.2024 23.05.2024 12.09.2024 06.12.2023 24.04.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-0,52%
1,91 €
ATH 26,76 €
-12,25% +4,73% -77,20% -75,94% -87,49%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL